US FDA Grants Emergency Use Authorization for Elanco's Dog Screwworm Treatment

The U.S. FDA has granted an Emergency Use Authorization for Elanco Animal Health's Credelio tablets to treat New World screwworm infestations in dogs, marking the first such authorization for an animal drug. This parasite, which was eradicated from the U.S. decades ago, has recently been detected near the southern border, prompting concerns about potential public health and national security threats. Credelio, previously approved for flea and tick control, has demonstrated 100% efficacy in clearing screwworm larvae within 24 hours in a small study. The authorization is temporary and valid only while the screwworm threat remains, with the FDA assessing that the drug's benefits outweigh its risks, despite possible side effects like tremors and seizures. Elanco, a significant player in animal pharmaceuticals with a market capitalization near $11 billion, operates globally and has expanded through acquisitions, although it faces challenges with revenue growth. This emergency approval provides veterinarians and pet owners with an immediate treatment option should screwworm infestations cross into the U.S.